Pre-analytical factors influencing the stability of cerebrospinal fluid proteins

Journal of Neuroscience Methods

Volumn 215, Issue 2, 2013, Pages 234-240

  Simonsen, Anja H ^a   Bahl, Justyna M C ^b   Danborg, Pia B ^a   Lindstrom, Veronica ^c   Larsen, Severin O ^b   Grubb, Anders ^c   Heegaard, Niels H H ^b   Waldemar, Gunhild ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; Immunoassays; Pre analytical factors; Proteome; SELDI TOF; Stability

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA 2 MICROGLOBULIN; CYSTATIN C; PHOSPHORYLATED TAU; PREALBUMIN; PROTEOME; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEINASE INHIBITOR;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; FREEZE THAWING; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN STABILITY; ROOM TEMPERATURE; STORAGE TEMPERATURE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ANALYSIS; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZING; LABORATORY DIAGNOSIS; MALE; MASS SPECTROMETRY; PROCEDURES; TEMPERATURE; TIME;

AMYLOID BETA-PEPTIDES; CEREBROSPINAL FLUID PROTEINS; COGNITION DISORDERS; CYSTATIN C; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZING; HUMANS; MALE; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; SPECIMEN HANDLING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TAU PROTEINS; TEMPERATURE; TIME FACTORS;

EID: 84877148563     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.03.011     Document Type: Article

References (24)

1. Berven F.S., Kroksveen A.C., Berle M., Rajalahti T., Flikka K., Arneberg R., et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl 2007, 1:699-711.
2. Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Ruther E., et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004, 25:2912-2918.
3. Bjerke M., Portelius E., Minthon L., Wallin A., Anckarsater H., Anckarsater R., et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, 2010.
4. Bruegel M., Planert M., Baumann S., Focke A., Bergh F.T., Leichtle A., et al. Standardized peptidome profiling of human cerebrospinal fluid by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Proteomics 2009, 72:608-615.
5. Del C.M., Mollenhauer B., Bertolotto A., Engelborghs S., Hampel H., Simonsen A.H., et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012, 6:419-430.
6. Fronek K., Lange P., Spreer A., Eiffert H., Nau R. Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of beta-Amyloid and Tau protein as determined by enzyme immunoassay. Dement Geriatr Cogn Disord 2011, 32:126-134.
7. Gauthier S., Kaur G., Mi W., Tizon B., Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci 2011, 3:541-554.
8. Jensen M., Hartmann T., Engvall B., Wang R., Uljon S.N., Sennvik K., et al. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 2000, 6:291-302.
9. Jimenez C.R., Koel-Simmelink M., Pham T.V., van d V., Teunissen C.E. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin Appl 2007, 1:1385-1392.
10. Kaiser E., Schonknecht P., Thomann P.A., Hunt A., Schroder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett 2007, 417:193-195.
11. Poulsen K., Bahl J.M., Tanassi J.T., Simonsen A.H., Heegaard N.H. Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods 2012, 56:284-292.
12. Rosenling T., Slim C.L., Christin C., Coulier L., Shi S., Stoop M.P., et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res 2009, 8:5511-5522.
13. Rosenling T., Stoop M.P., Smolinska A., Muilwijk B., Coulier L., Shi S., et al. The impact of delayed storage on the measured proteome and metabolome of human cerebrospinal fluid. Clin Chem 2011, 57:1703-1711.
14. Sancesario G.M., Esposito Z., Nuccetelli M., Bernardini S., Sorge R., Martorana A., et al. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?. Exp Neurol 2010, 223:371-376.
15. Schipke C.G., Jessen F., Teipel S., Luckhaus C., Wiltfang J., Esselmann H., et al. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. J Alzheimers Dis 2011, 26:255-262.
16. Schoonenboom N.S., Mulder C., Vanderstichele H., Van Elk E.J., Kok A., Van Kamp G.J., et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005, 51:189-195.
17. Simonsen A.H., Bech S., Laursen I., Salvesen L., Winge K., Waldemar G., et al. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J Neurosci Methods 2010, 191:244-248.
18. Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001, 47:1776-1781.
19. Southwick P.C., Yamagata S.K., Echols C.L., Higson G.J., Neynaber S.A., Parson R.E., et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996, 66:259-265.
20. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
21. Thompson E.J. Functional glossary. The CSF proteins: a biochemical approach 1988, 5-8. Elsevier, Amsterdam. E.J. Thompson (Ed.).
22. Vanderstichele H., Bibl M., Engelborghs S., Le B.N., Lewczuk P., Molinuevo J.L., et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012, 8:65-73.
23. Vanderstichele H., Van K.E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000, 7:245-258.
24. Zimmermann R., Lelental N., Ganslandt O., Maler J.M., Kornhuber J., Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 2011, 25:739-745.